Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guerin

G. N. Hortobagyi, H. Y. Yap, G. R. Blumenschein, J. U. Gutterman, A. U. Buzdar, C. K. Tashima, Evan M Hersh

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

One hundred and fourteen evaluable patients with measurable metastatic breast cancer were treated with a combination chemoimmunotherapy program (5-fluorouracil, adriamycin, and cyclophosphamide [FAC] - levamisole [LMS]. An additional 117 patients with similar characteristics were treated with the same program with the addition of bacillus Calmette-Guerin (BCG) by scarification (FAC-BCG-LMS). The results were compared to those observed in 44 evaluable patients treated with FAC chemotherapy alone. Overall remission rates were identical in the three studies (72%, 73% and 72%). The median duration of remission was 9 months for FAC, 13 months for FAC-LMS (P=0.07), and 14 months for FAC-BCG-LMS (P=0.05). The median duration of survival was 17 months for FAC and 28.6 months for FAC-LMS (P=0.01). Although the median survival for the FAC-BCG-LMS group has not been reached, it is significantly superior to FAC alone (P=0.009). These three sequential studies suggest that the addition of nonspecific immunotherapy with LMS or the combination of BCG and LMS prolongs the duration of remission and survival of responding patients treated with chemotherapy. Combination immunotherapy with BCG and LMS did not seem superior to LMS alone in this study.

Original languageEnglish (US)
Pages (from-to)1685-1692
Number of pages8
JournalCancer Treatment Reports
Volume62
Issue number11
StatePublished - 1978
Externally publishedYes

Fingerprint

Levamisole
Mycobacterium bovis
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Therapeutics
Immunotherapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hortobagyi, G. N., Yap, H. Y., Blumenschein, G. R., Gutterman, J. U., Buzdar, A. U., Tashima, C. K., & Hersh, E. M. (1978). Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guerin. Cancer Treatment Reports, 62(11), 1685-1692.

Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guerin. / Hortobagyi, G. N.; Yap, H. Y.; Blumenschein, G. R.; Gutterman, J. U.; Buzdar, A. U.; Tashima, C. K.; Hersh, Evan M.

In: Cancer Treatment Reports, Vol. 62, No. 11, 1978, p. 1685-1692.

Research output: Contribution to journalArticle

Hortobagyi, GN, Yap, HY, Blumenschein, GR, Gutterman, JU, Buzdar, AU, Tashima, CK & Hersh, EM 1978, 'Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guerin', Cancer Treatment Reports, vol. 62, no. 11, pp. 1685-1692.
Hortobagyi, G. N. ; Yap, H. Y. ; Blumenschein, G. R. ; Gutterman, J. U. ; Buzdar, A. U. ; Tashima, C. K. ; Hersh, Evan M. / Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guerin. In: Cancer Treatment Reports. 1978 ; Vol. 62, No. 11. pp. 1685-1692.
@article{3c2e4ca4eead4167b1ca4ffa17c1c2b5,
title = "Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guerin",
abstract = "One hundred and fourteen evaluable patients with measurable metastatic breast cancer were treated with a combination chemoimmunotherapy program (5-fluorouracil, adriamycin, and cyclophosphamide [FAC] - levamisole [LMS]. An additional 117 patients with similar characteristics were treated with the same program with the addition of bacillus Calmette-Guerin (BCG) by scarification (FAC-BCG-LMS). The results were compared to those observed in 44 evaluable patients treated with FAC chemotherapy alone. Overall remission rates were identical in the three studies (72{\%}, 73{\%} and 72{\%}). The median duration of remission was 9 months for FAC, 13 months for FAC-LMS (P=0.07), and 14 months for FAC-BCG-LMS (P=0.05). The median duration of survival was 17 months for FAC and 28.6 months for FAC-LMS (P=0.01). Although the median survival for the FAC-BCG-LMS group has not been reached, it is significantly superior to FAC alone (P=0.009). These three sequential studies suggest that the addition of nonspecific immunotherapy with LMS or the combination of BCG and LMS prolongs the duration of remission and survival of responding patients treated with chemotherapy. Combination immunotherapy with BCG and LMS did not seem superior to LMS alone in this study.",
author = "Hortobagyi, {G. N.} and Yap, {H. Y.} and Blumenschein, {G. R.} and Gutterman, {J. U.} and Buzdar, {A. U.} and Tashima, {C. K.} and Hersh, {Evan M}",
year = "1978",
language = "English (US)",
volume = "62",
pages = "1685--1692",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without bacillus Calmette-Guerin

AU - Hortobagyi, G. N.

AU - Yap, H. Y.

AU - Blumenschein, G. R.

AU - Gutterman, J. U.

AU - Buzdar, A. U.

AU - Tashima, C. K.

AU - Hersh, Evan M

PY - 1978

Y1 - 1978

N2 - One hundred and fourteen evaluable patients with measurable metastatic breast cancer were treated with a combination chemoimmunotherapy program (5-fluorouracil, adriamycin, and cyclophosphamide [FAC] - levamisole [LMS]. An additional 117 patients with similar characteristics were treated with the same program with the addition of bacillus Calmette-Guerin (BCG) by scarification (FAC-BCG-LMS). The results were compared to those observed in 44 evaluable patients treated with FAC chemotherapy alone. Overall remission rates were identical in the three studies (72%, 73% and 72%). The median duration of remission was 9 months for FAC, 13 months for FAC-LMS (P=0.07), and 14 months for FAC-BCG-LMS (P=0.05). The median duration of survival was 17 months for FAC and 28.6 months for FAC-LMS (P=0.01). Although the median survival for the FAC-BCG-LMS group has not been reached, it is significantly superior to FAC alone (P=0.009). These three sequential studies suggest that the addition of nonspecific immunotherapy with LMS or the combination of BCG and LMS prolongs the duration of remission and survival of responding patients treated with chemotherapy. Combination immunotherapy with BCG and LMS did not seem superior to LMS alone in this study.

AB - One hundred and fourteen evaluable patients with measurable metastatic breast cancer were treated with a combination chemoimmunotherapy program (5-fluorouracil, adriamycin, and cyclophosphamide [FAC] - levamisole [LMS]. An additional 117 patients with similar characteristics were treated with the same program with the addition of bacillus Calmette-Guerin (BCG) by scarification (FAC-BCG-LMS). The results were compared to those observed in 44 evaluable patients treated with FAC chemotherapy alone. Overall remission rates were identical in the three studies (72%, 73% and 72%). The median duration of remission was 9 months for FAC, 13 months for FAC-LMS (P=0.07), and 14 months for FAC-BCG-LMS (P=0.05). The median duration of survival was 17 months for FAC and 28.6 months for FAC-LMS (P=0.01). Although the median survival for the FAC-BCG-LMS group has not been reached, it is significantly superior to FAC alone (P=0.009). These three sequential studies suggest that the addition of nonspecific immunotherapy with LMS or the combination of BCG and LMS prolongs the duration of remission and survival of responding patients treated with chemotherapy. Combination immunotherapy with BCG and LMS did not seem superior to LMS alone in this study.

UR - http://www.scopus.com/inward/record.url?scp=0018231124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018231124&partnerID=8YFLogxK

M3 - Article

C2 - 728894

AN - SCOPUS:0018231124

VL - 62

SP - 1685

EP - 1692

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11

ER -